2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 21

Factor Xa Reactive Antibodies In Patients With Systemic LUPUS Erythematosus and Antiphospholipid Syndrome Have Differential Effects Upon Coagulation Assays and Endothelial CELLS
Abstract Number: 2292

Factors Affecting The Discrepancy Between Physician and Patient Global Assessment Of Disease Activity In Early and Established Rheumatoid Arthritis Patients- Results From The Ontario Best Practices Initiative
Abstract Number: 603

Factors Associated With a Double Increase In Serum Creatinine In Biopsy Proven Lupus Nephritis From a Single Center In Spain
Abstract Number: 1027

Factors Associated With Decisions To Adjust Therapy For Rheumatoid Arthritis Patients In Moderate To High Disease Activity
Abstract Number: 600

Factors Associated With Long-Term Renal Function Deterioration In Lupus Nephritis Treated Initially With Combined Prednisolone and Mycophenolate Mofetil (MMF) Or Tacrolimus (Tac)
Abstract Number: 2130

Factors Associated With Two-Year Pain Experience Outcome In Knee Osteoarthritis
Abstract Number: 347

Factors Explaining The Discrepancy Between Patient and Physician Global Assessment Of Disease Activity In Psoriatic Arthritis
Abstract Number: 1350

Factors Influencing Selection Of Biologic Therapy and Comparative Effectiveness In Patient Reported Outcomes Among Patients With Rheumatoid Arthritis
Abstract Number: 832

Factors That Affect Tender and Swollen Joint Counts In Rheumatoid Arthritis
Abstract Number: 1917

Falls Among Hospitalized Orthopedic Patients: A Prospective Case-Control Study
Abstract Number: 180

Familial Aggregation Of Female Premenopausal Gout –Monogenic, Polygenic Or Clinical Coincidence?
Abstract Number: 2235

Fas Signaling In Macrophages Promotes Chronicity In K/BxN Serum Transfer Induced Arthritis
Abstract Number: 2667

Fast-Track Pathway In Giant Cell Arteritis: A Cost-Effectivenss Analysis
Abstract Number: 2474

Fat Mass and Resistin: Predictive Factors For Anti-TNF Therapy Response In Ankylosing Spondylitis Patients
Abstract Number: 337

Fatigue and Work Disability In Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].